quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·64d
PRRelease
Crescent Biopharma Inc. logo

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

CBIO· Crescent Biopharma Inc.
Health Care
Original source

Companies

  • CBIO
    Crescent Biopharma Inc.
    Health Care

Recent analyst ratings

  • Jan 28UpdatePiper Sandler$35.00
  • Jan 21UpdateGuggenheim$35.00
  • Aug 25UpdateJefferies$26.00
  • Aug 11UpdateH.C. Wainwright$25.00
  • Jul 14UpdateWedbush$27.00
  • Jun 25UpdateStifel$28.00

Related

  • SEC2d
    SEC Form DEFA14A filed by Crescent Biopharma Inc.
  • SEC2d
    SEC Form DEFA14A filed by Crescent Biopharma Inc.
  • SEC2d
    SEC Form DEF 14A filed by Crescent Biopharma Inc.
  • PR27d
    Crescent Biopharma Announces Grants of Inducement Awards
  • SEC37d
    SEC Form 424B3 filed by Crescent Biopharma Inc.
  • PR48d
    Crescent Biopharma Announces Grants of Inducement Awards
  • SEC51d
    SEC Form EFFECT filed by Crescent Biopharma Inc.
  • SEC52d
    SEC Form POS AM filed by Crescent Biopharma Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022